Search
-
Opinion Polls: Why They Remain the Reference
The last year has seen opinion and election polling subjected to both criticism and praise. Here we review the evidence, looking particularly at recent experiences in the US, UK, France and the Netherlands.
-
Taking Responsibility - Giving Back to the Underprivileged in Lebanon
The month of Ramadan is about giving and lending a helping hand to others; this is exactly what the team in Lebanon did this year.
-
[EVENT] NASPL Professional Development Seminar
On July 24, join Ipsos lottery & gaming experts for two insightful presentations at this year’s NASPL professional development conference.
-
[EVENT] 5th Annual International Colloquium on Branding
5th Annual International Colloquium on Branding 24-27 July 2017, Athens, Greece sponsored by the Athens Journal of Business & Economics.
-
Ipsos Public Affairs in France and the Parliamentary Elections
Once again, the Ipsos Public Affairs France team, led by Brice Teinturier (Deputy CEO, Ipsos in France) and Jean-François Doridot (BU Manager, Ipsos Public Affairs in France), announced live estimates very close to the official scores for both parliamentary election rounds!
-
The Most Influential Brands in Australia 2017
Ipsos has released 2017’s Most Influential Brands study. Polling 2000 Australians, it looks at key drivers that define ‘influence’ and five complementary factors that impact it.
-
Ipsos in Canada Takes Three Awards in Research Excellence
Ipsos has been privileged to work with exceptional Canadian clients on inspiring programs, and a select number of these were recognised at the June 1, 2017 Excellence in Research Awards Gala hosted by the Marketing Research and Intelligence Association (MRIA).
-
2017 US Politics - Trump is Struggling to Improve his Approval Rating (June 21)
In the latest Reuters/Ipsos Core Political, healthcare continues to dominate the news cycle, cementing its place as Americans’ top priority
-
Conquering Complexity: The coming revolution in oncology biomarker testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.